Marker Therapeutics Shares Double After Hours, FDA Approves IND for MT-601
August 04 2022 - 6:28PM
Dow Jones News
By Stephen Nakrosis
Shares of Marker Therapeutics Inc. jumped in after-hours trading
Thursday, following news the U.S. Food and Drug Administration
approved the company's investigational new drug application for
MT-601 to treat certain patients with non-Hodgkin lymphoma.
At 5:54 p.m. ET, the company's shares were trading 100% higher
at 66 cents a share. Volume in the after-hours market was over 2.4
million shares.
Peter L. Hoang, the company's president and chief executive,
said, "FDA clearance of our IND for MT-601 is a significant
milestone as we advance our pipeline in a number of
company-sponsored trials." He added that MT-601 targets six
tumor-associated antigens highly expressed in lymphoma, and said,
"we look forward to initiating our company-sponsored Phase 1 study
next year."
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
August 04, 2022 18:13 ET (22:13 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart
From Apr 2023 to Apr 2024
